Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 21% of the time (143 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-11-07. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientleftventricularfailurelung
  Phrases that lowered it: mmhgpressureeffectrespiratoryscreening
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Sponsor's past termination rate: 7.8% (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 80 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 67.2% (lowers risk) · Drug's FDA history
• Blinding: triple (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 293 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 23.2% (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Maximum age: 75 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS) NCT02622724 · started 2015 · scored riskier than 52% of active trials terminated
• A Combination of an Inhaled Budesonide and Ipratropium in Patients at Risk of Developing ARDS NCT06657079 · started 2024 · scored riskier than 62% of active trials completed
• Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS NCT03567577 · started 2018 · scored riskier than 40% of active trials completed
• A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19 NCT04640194 · started 2020 · scored riskier than 39% of active trials completed
• Iloprost in Acute Respiratory Distress Syndrome NCT03111212 · started 2019 · scored riskier than 65% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.